Share

September 2020; 7 (5) ArticleOpen Access

High κ free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis

Adi Wilf-Yarkoni, Yifat Alkalay, Talma Brenner, Arnon Karni
First published July 14, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000831
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
842

Share

Abstract

Objective To investigate the hypothesis that free light chain (FLC) sera levels could serve as a biomarker for myasthenia gravis (MG), especially for the subgroups of seronegative MG and ocular MG.

Methods Sera from 73 patients with MG (20 seronegative for antiacetylcholine receptor [AChR] and anti–muscle-specific kinase and 53 positive for anti-AChR, which were clinically divided into 24 patients with ocular type, 45 with generalized type, and 4 with unequivocal clinical manifestation) and 49 healthy controls were studied for κ FLC and λ FLC levels with the Freelite human FLC kits.

Results The κ but not the λ levels of FLC were significantly increased in the patients with MG, including those with double seronegative MG and ocular MG, compared with the healthy controls. The specificity for double seronegative MG and ocular MG were both 98.0% when κ FLC was ≥25.0 mg/L. Increased κ FLC levels were not affected by the patient's sex, age at MG onset, the presence of thymic pathology, or different treatments.

Conclusions Elevated serum κ FLC may serve as a biomarker for MG in suspected patients who are double seronegative and in those with only ocular manifestations when serology is inconclusive.

Classification of evidence This study provides Class III evidence that high κ FLC levels distinguished patients with MG, including those who were double seronegative, from healthy controls.

Glossary

AChR=
acetylcholine receptor;
ANA=
antinuclear antibody;
ARR=
absolute risk reduction;
ENA=
extracted nuclear antibody;
FLC=
free light chain;
G-MG=
generalized myasthenia gravis;
HC=
healthy control;
IVIg=
IV immunoglobulin;
LRP4=
lipoprotein receptor–related protein 4;
MG=
myasthenia gravis;
MuSK=
muscle-specific kinase;
NNT=
number needed to treat;
O-MG=
ocular myasthenia gravis;
ROC=
receiver operating characteristic;
SN-MG=
serum-negative myasthenia gravis;
SP-MG=
serum-positive myasthenia gravis;
TPO=
thyroid peroxidase

Myasthenia gravis (MG) is an antibody-mediated autoimmune disease affecting the postsynaptic neuromuscular junctions of striated skeletal muscles.1,–,3 The clinical manifestation includes muscle weakness, which can be localized to ocular muscles (ocular MG [O-MG]) or distributed in extraocular muscles (generalized MG [G-MG]).2 The diagnosis of MG is confirmed by the combination of symptoms, electrical physiologic studies demonstrating neuromuscular junction dysfunction, and a positive test for specific antibodies.4,5 Antibodies against acetylcholine receptors (AChRs),6 muscle-specific kinase (MuSK),7 and lipoprotein receptor–related protein 4 (LRP4)3,8 can be found in about 90% of patients with MG (seropositive [SP]), and about 10% remain with undetected specific autoantibody (seronegative [SN]).1 The diagnosis of MG may be obscure in SN patients. The failure in finding a specific antibody for MG leaves a degree of insecurity in the diagnosis of SN-MG, and it is recommended that serologic tests be repeated several months following negative test results.1 A biomarker for MG in these patients may therefore add confidence in the diagnosis of MG.

The production of antibodies is generally also accompanied by the synthesis of immunoglobulin light chains. The circulating levels of light chains may be increased in conditions of excess immunoglobulin production, as in antibody-mediated diseases and in renal failure.9,10 Recent studies have demonstrated that this overproduction of light chains has a biological and immunologic role.9 An increase in free light chain (FLC) production has been reported in several autoimmune diseases.11,–,17

To the best of our knowledge, only 1 study has evaluated FLC levels in MG, and it reported an elevation of both κ FLC and λ FLC in their 34 study patients.18 We hypothesized that κ FLC and λ FLC levels may be biomarkers for MG, especially for SN-MG for which diagnosis can be difficult. Therefore, we studied the κ FLC and λ FLC levels in patients with MG, including those with SN-MG, and in healthy controls (HCs). We also analyzed the results according to various clinical forms of the disease in a large number of patients with MG.

Methods

Standard protocol approvals, registrations, and patient consent

The study protocol was approved by the Tel Aviv Sourasky Medical Center Institutional Review Board for human experiments (Helsinki Committee, No. 0702-15). All the participants signed written informed consent.

Study design

This is a case-control prospective study that compares the levels of FLCs in the sera of patients with MG and of HCs.

Patients and controls

One hundred twenty-eight potential donors who include 79 consecutive patients with MG and 49 healthy volunteers were screened. Sixteen of the patients were excluded (because of the exclusion criteria that are listed below and in the flow diagram [supplementary data, links.lww.com/NXI/A281]). To increase the number of subjects with SN-MG, we invited an additional 10 patients who were known to have SN-MG to participate in the study. Overall, blood samples were drawn between 2017 and 2019 from 73 patients with MG who were referred to the Neuroimmunology Unit at the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, and from 49 healthy individuals who served as controls (HCs) (table). The diagnosis of MG was defined by clinical and supportive features of neurophysiology tests of single-fiber EMG and/or serology of AChR antibodies or anti-MuSK antibodies. The patients underwent a chest CT scan or a chest MRI scan, and those with radiologic evidence of thymus enlargement or a suspected thymoma underwent thymectomy.

View this table:
Table

Demographic and clinical characteristics of the patients

The distribution of patients according to the Myasthenia Gravis Foundation of America clinical classification was Class I = 24 patients, Class IIA = 20 patients, Class IIB = 4 patients, Class IIIA = 9 patients, Class IIIB = 6 patients, Class IVA = 4 patients, and Class IVB = 2 patients. The classification of 4 patients was equivocal. Class I, which is ocular MG (O-MG), was diagnosed in patients with pure ocular involvement lasting over 2 years because 90% of them will be presumed to remain with ocular MG throughout their illness.19 The disease duration among these patients was between 2 and 3 years in 2 patients, between 3 and 5 years in 6 patients, and above 5 years in 16 patients.

The diagnosis of patients with SN-MG was based on fluctuating muscular weakness in a typical distribution for MG with supportive positive diagnostic tests of single-fiber EMG and/or repetitive stimulation EMG and/or positive edrophonium tests in addition to ruling out other relevant medical conditions that may present with the same type of weakness (such as thyroid ophthalmopathy, congenital myasthenia, Lambert-Eaton myasthenic syndrome, myositis, mitochondrial syndromes, amyotrophic lateral sclerosis, and CNS demyelinating diseases) by the clinical presentation and course, relevant blood tests, EMG, and brain MRI in patients who had negative tests for anti-AChR and anti-MuSK antibodies. Patients were treated according to the accepted guidelines.

The exclusion criteria were a diagnosis of plasma cell dyscrasia disorders, a diagnosis or suspicion of another chronic inflammatory condition known to be associated with increased serum levels of FLC (such as rheumatoid arthritis, systemic sclerosis, Sjögren syndrome, and systemic lupus erythematosus),10,14 a glomerular filtration rate of <60 mL/min/1.73 m2, and treatment with plasmapheresis for the past 3 months. We recruited healthy individuals to serve as the control group to test whether FLC levels are high in the sera of patients with MG. The data collection was planned before the tests for FLCs were performed.

Laboratory testing

Blood serum samples were separated by standard centrifugation, divided into aliquots, and stored frozen until analysis. The samples were then assayed in a blinded fashion. FLC serum levels were assessed with the Freelite Human κ and λ Free Kits (The Binding Site Ltd., Birmingham, United Kingdom) on a SPAPLUS instrument (The Binding Site Ltd.). Anti-AChR Ab was tested by ELISA (EUROIMMUN AG, Luebeck, Germany). Anti-MuSK Ab was assessed by RIA with the MuSK kit (RSR Ltd., Cardiff, United Kingdom). Antinuclear antibody (ANA), antimitochondrial, and antismooth muscle were tested by immunofluorescence (AESKU GROUP, Wendelsheim, Germany). Extracted nuclear antibodies (ENAs) including antibodies against SSA, SSB, RNP SM, JO1, and SCL70, as well as antibodies against histone, dsDNA, thyroglobulin, and thyroid peroxidase (TPO), were tested by ELISA (Alegria by ORGENTEC Diagnostika GmbH, Mainz, Germany). Rheumatoid factor was assessed by a nephelometric BNtmII System by Siemens Medical Solutions, Malvern, PA.

Primary research questions

Can κ FLC and λ FLC levels be biomarkers for patients with MG and for patients with double SN-MG.

Statistical analysis

Data for group comparisons are presented as mean ± SD and with 95% confidence intervals (CIs). Statistical analysis and the graphical representation of the data were performed with GraphPad Prism (version 8.2.1; GraphPad Software, San Diego, CA), SPSS (version 22; SPSS Inc., Chicago, IL). Comparisons between 2 groups were performed using the Student unpaired t test with Welch's correction when the variances were unequal. The Welch analysis of variance test was applied to compare multiple group differences for unequal variance, and the Dunnett T3 multiple comparisons test was used to compare within-group differences. A p value of <0.05 was considered statistically significant. A multivariate analysis was performed to evaluate possible confounding effects. A receiver operating characteristic (ROC) curve analysis for calculating the area under the ROC curve was used to determine the diagnostic accuracy of FLC values as diagnostic markers for MG. The number needed to treat (NNT) and absolute risk reduction (ARR) were added when an estimation of cutoff levels of FLC was analyzed. The Pearson correlation coefficient was applied to test correlations between anti-AChR and FLC levels.

Data availability

Anonymized data will be shared by request from any qualified investigator.

Results

The 122 participants in this study included 73 patients with MG (42 men and 31 women), with a mean age of (mean ± SD) 59.1 ± 14.2 years, and 49 HCs (21 men and 28 women) with a mean age of 43.4 ± 12.8 years. The patients' clinical manifestations, serologic results, sex, and age at MG onset are summarized in table. There were 53 patients with detectable anti-AChR antibodies in the serum and 20 patients with negative results for anti-AChR and anti-MuSK.

FLC levels in patients with MG and according to serologic status

The κ FLC serum levels were higher in the patients with MG compared with the HCs (23.7 ± 8.3 mg/L, CI = 21.8–25.68 mg/L and 15.9 ± 5.0 mg/L, CI = 14.5–17.3 mg/L, respectively, p < 0.0001, figure 1A). However, there were no significant differences in their λ FLC serum levels (15.9 ± 5.7 mg/L, CI = 14.6–17.2 mg/L and 14.5 ± 4.6 mg/L, CI = 13.2–15.8 mg/L, respectively, p = N.S., figure 1B). Moreover, there was a significant increase in the κ/λ ratio in the patients with MG compared with the HCs (1.5 ± 0.41, CI = 1.4–1.6 and 1.1 ± 0.2, CI = 1.0–1.2, respectively, p < 0.0001, figure 1C). These increased κ FLC levels in the patients with MG compared with the HCs were confirmed after correction for age and sex in a multivariant analysis (F = 16.34, p < 0.001).

Figure 1
Figure 1 FLC levels in patients with MG and according to serologic status

Free light chain (FLC) levels in the sera of patients with seropositive myasthenia gravis (SP-MG) and patients with double seronegative MG (SN-MG). Serum κ (A) and λ (B) FLC levels and the κ/λ ratio (C) in patients with MG and healthy controls (HCs). Serum κ (D) and λ (E) FLC levels and the κ/λ ratio (F) in patients with double SN-MG, in patients with SP-MG for antiacetylcholine receptor antibody, and in HCs. A receiver operating characteristic curve for κ FLC in patients with double SN-MG (G). Significant p values for the t test and Dunnett T3 multiple comparisons test are displayed: *p < 0.01; and **p < 0.0001.

One of the main objectives of this study was to test the FLC serum levels in patients who tested negative for antibodies against both AChR and MuSK (double SN-MG). The κ but not the λ FLC levels differed significantly among the 3 groups (p < 0.0001). A multiple comparisons test revealed a significant increase in κ FLC in the patients with double SN-MG (n = 20, 26.8 ± 12.0 mg/L, CI = 21.5–32.0 mg/L) compared with the HCs (p < 0.002, figure 1D). There was no significant difference in κ FLC levels between double SN patients and SP patients for anti-AChR (n = 53, 22.5 ± 6.2 mg/L, CI = 20.8–24.2 mg/L, p = N.S.). The κ/λ ratio, however, differed significantly among the 3 groups (p < 0.0001). There was a significant increase in the κ/λ ratio in the patients with SN-MG (1.6 ± 0.5, CI = 1.4–1.9) compared with the HCs (p < 0.001, figure 1F). None of the study patients were found to have anti-MuSK antibodies.

The difficulties in diagnosing MG in patients who have negative serology tests for myasthenia-specific autoantibodies establish a clear-cut need for a biomarker(s) for this patient subgroup. A ROC analysis for κ FLC in patients with double SN-MG has an area under the curve of 0.79, CI = 0.65–0.91, p = 0.0002 (figure 1G). For example, the calculated specificity of κ FLC ≥25 mg/L of patients with double SN-MG compared with HCs was 98.0%, with a sensitivity of 45.0%, NNT = 2.2, and ARR = −0.45.

The sera of all patients with double SN-MG were tested for ANA, ENA (that includes antibodies against SSA, SSB, RNP, SM, JO1, and SCL70), antibodies against histone, dsDNA, thyroglobulin, TPO, mitochondrial, smooth muscle, and rheumatoid factor. We found that 1 patient was positive for ANA (homogenous pattern), anti-dsDNA, and anti-histone (κ FLC = 15.5 mg/L and λ FLC = 11.4 mg/L). Another patient with double SN-MG was positive for TPO (κ FLC = 16.9 mg/L and λ FLC = 11.7 mg/L). We did not find any correlation between the levels of anti-AChR and κ FLC (r = −0.059) or λ FLC (r = −0.044).

FLC levels in patients with MG according to clinical characteristics

We compared the FLC levels in MG subgroups according to clinical manifestations, age at MG onset, and thymus pathology. Figure 2, A and B shows the κ and λ FLC levels in the O-MG, G-MG, and HC groups. The κ FLC but not the λ FLC levels differed significantly among the 3 groups (p < 0.0001). A multiple comparisons test revealed an increase in κ FLC in the O-MG group (n = 24, 23.0 ± 6.2 mg/L, CI = 20.0–25.0 mg/L) compared with the HC group (15.9 ± 5.0 mg/L, CI = 14.5–17.3 mg/L, figure 2A). There was no difference between the O-MG and G-MG groups (23.8 ± 9.2, CI = 21.1–26.5 mg/L).

Figure 2
Figure 2 FLC levels according to MG subgroups

Serum κ (A) and λ (B) free light chain (FLC) levels in patients with pure ocular myasthenia gravis (O-MG) and patients with generalized myasthenia gravis (G-MG). A receiver operating characteristic curve for κ FLC in patients with O-MG (C). Serum κ (D) and λ (E) FLC levels in early-onset myasthenia gravis (EO-MG, age ≤50 years) and late-onset myasthenia gravis (LO-MG, age >50 years). Serum κ (F) and λ (G) FLC levels in MG patients with thymus pathology and normal thymus. HC = healthy control.

Given that the diagnosis of ocular MG may often be challenging, there is a need for a biomarker for ocular MG. The ROC analysis for κ FLC in patients with ocular MG had an area under the curve of 0.81, 95% CI = 0.71–0.91 (figure 2C). For example, the calculated specificity of κ FLC ≥25 mg/L of patients with O-MG compared with the HCs was 98.0%, with a sensitivity of 37.5%, NNT = 2.7, and ARR = −0.375. There was an increase in the κ/λ ratio between O-MG (1.5 ± 0.5, CI = 1.3–1.7) and G-MG (1.5 ± 0.4, CI = 1.4–1.6) groups and the HCs (1.1 ± 0.2, CI = 1.0–1.2).

Early-onset MG was defined as onset at ≤50 years of age, and late-onset MG was defined as onset >50 years of age.5 There was also no difference in the κ FLC and λ FLC levels between patients with early-onset MG (n = 21, 20.9 ± 6.5 mg/L, CI = 18.1–23.6 mg/L and 14.7 ± 4.5 mg/L, CI = 12.7–16.6 mg/L, respectively) and patients with late-onset MG (n = 52, 24.8 ± 8.8 mg/L, CI = 22.4–27.2 mg/L and 16.4 ± 6.2 mg/L, CI = 14.8–18.1 mg/L, respectively) (figure 2, C and D). Twelve patients with MG had an abnormal thymus, including 2 patients with thymoma and 10 patients with thymus hyperplasia. An analysis of those patients revealed no difference in the κ FLC and λ FLC levels between patients with thymic pathology (23.8 ± 8.2 mg/L, CI = 19.2–28.4 and 16.8 ± 4.9 mg/L, CI = 14.0–19.5 mg/L, respectively) and those patients without (22.6 ± 6.6 mg/L, CI = 20.7–24.4 and 15.6 ± 4.7 mg/L, CI = 14.3–16.9 mg/L, respectively, figure 2, E and F). Twenty-eight of the patients were being regularly treated by IV immunoglobulin (IVIg) at a dose of 0.4 g/kg every 3–6 weeks. A blood sample from these patients was always taken just before the next IVIg treatment. There was no difference in the κ FLC and λ FLC levels between the patients with IVIg-treated MG (22.7 ± 7.8 mg/L, CI = 19.8–25.6 and 16.4 ± 5.3 mg/L, CI = 14.4–18.3 mg/L, respectively) and the patients with non-IVIg--treated MG (23.0 ± 6.1 mg/L, CI = 21.0–25.1 and 15.7 ± 4.2 mg/L, CI = 14.3–17.1 mg/L, respectively). There were no differences in κ FLC and λ FLC levels between patients who were treated with pyridostigmine alone (n = 22, 22.4 ± 6.6 mg/L, CI = 19.6–25.2 and 15.5 ± 3.9 mg/L, CI = 14.0–17.1 mg/L, respectively) and those who were also treated with prednisone and/or azathioprine but not IVIg (n = 22, 22.6 ± 3.3 mg/L, CI = 21.2–23.9 mg/L and 14.3 ± 4.4 mg/L, CI = 12.5–16.2 mg/L, respectively) and those who were treated with IVIg. One patient was treated with rituximab.

Consistently high κ FLC levels

To assess the reliability of FLC measurements, serum was collected once more from 28 patients with MG at an average interval of 6 months. The statistical analysis with a paired t test revealed no significant difference between the 2 samples (22.3 ± 6.8 mg/L, CI = 19.8–24.8 mg/L vs 21.4 ± 7.4 mg/L, CI = 18.6–24.2 mg/L). The mean ± SD of percentage of change between the sample pairs was 16.0% ± 11.9%, CI = 11.6–20.4.

Discussion

The search for the biological role and possible clinical application of FLC in various autoimmune diseases has become an area of growing interest. A number of studies have demonstrated that FLCs are not a waste of immunoglobulin synthesis but rather active molecules with immunologic properties. FLCs have been shown to participate in several key processes of immune responses. They are necessary to adjust polymorphonuclear function and stimulation,20 they cause mast cell degranulation that releases proinflammatory mediators,21 and they may have direct toxicity in the kidney.9 Overproduction of FLC may occur after an excess of antibody production by B cells, usually as a result of chronic immune stimulation. Therefore, the measurement of FLC has been proposed as a biomarker of B-cell activity.10

Little is known about FLC in MG. The main result of our current study is the finding that patients with MG have higher levels of serum κ FLC but not of λ FLC compared with HCs. Furthermore, and even more important, we observed that the levels of κ FLC are high in patients with double SN-MG compared with HCs. This is a heretofore unreported immunologic finding of double SN-MG. The differential diagnosis of patients with suspected SN-MG is according to the patient's specific clinical expression, and the diagnostic investigation is by verification of the clinical course and manifestations, blood tests, electromyographic tests, and imaging studies. For patients who were not diagnosed with another disease, a high level of κ FLC and of the κ/λ ratio may serve as a supportive biomarker for MG, when there is no comorbidity with a known medical condition that is associated with high FLC levels. Also, none of our patients with double SN-MG were diagnosed with any other diseases known to have high FLC levels, 2 of our patients with double SN-MG tested positive to autoantibodies (1 had positive ANA, anti-dsDNA, and anti-histone, and the other had positive TPO). Because the FLC levels in these patients were low, and therefore did not contribute to the overall increase in κ FLC levels in this patient group, we did not exclude them from the analysis.

It is important to emphasize that being a biomarker does not make κ FLC a diagnostic test for MG, as the antibodies against postsynaptic antigen of the neuromuscular junction, but at a high value and under the above-mentioned clinical conditions, it supports the diagnosis of MG. This finding suggests overactivity of plasma cells in this patient subgroup. It is conceivable, therefore, that there is a postsynaptic-directed antibody production that has not yet been identified, or that the current methods are not sensitive enough to detect it in this subgroup of patients with double SN-MG.22

Clinical presentation, age at MG onset, and the presence of thymus pathology did not affect the κ FLC levels that were high in both O-MG and G-MG patients as well as among the early-onset and late-onset MG patients. O-MG is often part of the differential diagnosis of disorders of the brainstem, ocular motor nerves, and eye muscles, and the confirmatory tests of edrophonium, serum AChR antibodies, and electromyographic evaluations may fail to support the diagnosis of O-MG.23 Our results suggest that high levels of κ FLC can serve as a biomarker to support the diagnosis of O-MG in these cases.

Twenty-eight of our patients with MG were treated with IVIg, but we did not find any effect of this therapy on their FLC levels when their blood sample was drawn just before the next scheduled treatment. This observation can be explained by the fact that although IVIg solutions contain FLC, their half-life is only a few hours. There were also no differences in κ FLC levels in these patients and the patients who were treated with pyridostigmine alone or with immunosuppressive agents without IVIg. Our results, therefore, suggest no treatment effect on κ FLC levels.

Our results of elevated κ FLC levels in patients with MG are in line with recent observations in 34 serum samples from 17 AChR-positive and 13 MuSK-positive patients.18 However, those authors found a significant increase in free λ chain levels as well. A review of their data reveals that the patients' free λ chain levels were higher than those of the controls but were within the normal range, whereas the κ/λ ratio was significantly higher in both MG groups, which indicates substantial increases in free κ FLC. The explanation for increased κ FLC levels in autoimmune diseases is not clear. This finding could possibly be explained by the dominance of κ FLC in humans because the κ chain is rearranged first during IgG production and is quantitatively more common.16,24 Furthermore, λ FLC is usually dimeric in form, whereas κ FLC is generally monomeric but can exist as noncovalently linked dimers.25 In addition, the 2 forms of FLC probably serve as different modulators of the immunologic response because λ FLCs are more effective silencers of autoreactive B cells,26 which may explain why the κ FLC level is more elevated in classic autoimmune diseases, such as MG.

A high κ FLC level was also shown to be associated and to have prognostic value in several autoimmune conditions. Specifically, serum κ chains and κ/λ ratios were significantly higher in systemic sclerosis and correlated with disease activity.11 Moreover, κ chains were significantly and strongly correlated with disease activity in Sjögren syndrome, and patients with systemic lupus erythematosus demonstrated elevated concentrations of serum FLC (mainly κ chains), with a strong inverse correlation having been found between the κ chain levels and the C3 levels.11,12 CSF κ FLC levels have a high sensitivity and specificity for the diagnosis of MS, and they can predict conversion from a clinically isolated syndrome to MS.15,–,17

The diagnosis of MG may be challenging, especially in patients with no detectable antibodies in their serum. To the best of our knowledge, this is the first description of elevated κ FLC levels in patients with double SN-MG. The measurement of κ FLC is reliable, inexpensive, and rapid and therefore readily available for supporting the possible diagnosis of these patients.

Our study has several limitations. The number of SN patients is relatively small because only about 10% of patients with MG are SN. We intentionally recruited a higher proportion of SN patients who comprised 27.4% of the studied MG group to be able to test the hypothesis of increased FLC levels in this patient subgroup. Indeed, we found significantly increased levels of κ FLC in patients with double SN-MG. A larger group of SN subjects would have allowed stronger support for these results. Anti-LRP4 antibody and anticlustered AChR antibody were not evaluated, and anti-MuSK was not detected in our patients. Therefore, we could not study the levels of FLC in patients who are positive to one or more of these autoantibodies or in patients who are also negative for anti-LRP4 and anticlustered AChR antibodies. Because these tests are not available in many centers, we believe that the relatively simple test for determining FLC levels can support the diagnosis of MG in such situations. Our control group comprised healthy individuals and not patients with other diseases that can mimic MG; therefore, our conclusions are limited to cases that those mimickers were ruled out.

Elevation in κ FLC levels is not specific for MG, and it can be found in hematologic malignancies and in other autoimmune diseases. Therefore, κ FLC can serve as a biomarker only in patients whose clinical manifestations suggest the possibility of MG and who do not have any other disorder known to be associated with increased κ FLC levels. In conditions in which the only diagnostic support for MG is a high κ FLC level, and after ruling out other disorders that are associated with high κ FLC levels, it would be appropriate to consider performing hematologic and immunologic tests for these disorder markers to rule them out. Because we did not assess the association between FLC levels with disease activity, severity, and response to therapy, we cannot comment on the use of FLC as a biomarker for MG activity, as reported in other autoimmune diseases,9,10,14,25 or for the possibility of its being a marker of response to therapy. Further investigation is needed to study these questions.

In conclusion, our data support the use of κ FLC as a biomarker for MG, especially in patients with double SN-MG and in patients suspected of having O-MG for which a high κ FLC level seems to be specific for MG.

Study funding

The study was funded in part by The Binding Site Group Ltd. and by Medison Pharmaceuticals Ltd.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Acknowledgment

The authors thank Ms. Esther Eshkol, the institutional medical copyeditor, for editing the manuscript for nonintellectual content.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the Medical Research Infrastructure of TASMC.

  • Class of Evidence: NPub.org/coe

  • Received February 29, 2020.
  • Accepted in final form May 29, 2020.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Gilhus NE
    . Myasthenia gravis. N Engl J Med 2017;376:e25.
    OpenUrl
  2. 2.↵
    1. Gilhus NE,
    2. Verschuuren JJ
    . Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14:1023–1036.
    OpenUrlCrossRef
  3. 3.↵
    1. Berrih-Aknin S,
    2. Le Panse R
    . Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014;52:90–100.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Zisimopoulou P,
    2. Brenner T,
    3. Trakas N,
    4. Tzartos SJ
    . Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013;12:924–930.
    OpenUrl
  5. 5.↵
    1. Berrih-Aknin S,
    2. Frenkian-Cuvelier M,
    3. Eymard B
    . Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 2014;48–49:143–148.
    OpenUrlCrossRef
  6. 6.↵
    1. Vincent A,
    2. Newsom-Davis J
    . Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246–1252.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Evoli A,
    2. Tonali PA,
    3. Padua L, et al
    . Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304–2311.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Zisimopoulou P,
    2. Evangelakou P,
    3. Tzartos J, et al
    . A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014;52:139–145.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Esparvarinha M,
    2. Nickho H,
    3. Mohammadi H,
    4. Aghebati-Maleki L,
    5. Abdolalizadeh J,
    6. Majidi J
    . The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. Biomed Pharmacother 2017;91:632–644.
    OpenUrl
  10. 10.↵
    1. Napodano C,
    2. Pocino K,
    3. Rigante D, et al
    . Free light chains and autoimmunity. Autoimmun Rev 2019;18:484–492.
    OpenUrl
  11. 11.↵
    1. Bosello S,
    2. Basile U,
    3. De Lorenzis E, et al
    . Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. J Clin Pathol 2018;71:620–625.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Chiche L,
    2. Cournac JM,
    3. Mancini J, et al
    . Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 2011;30:685–689.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Gottenberg JE,
    2. Aucouturier F,
    3. Goetz J, et al
    . Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007;66:23–27.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Gulli F,
    2. Napodano C,
    3. Marino M, et al
    . Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases. Clin Exp Immunol 2020;199:163–171.
    OpenUrl
  15. 15.↵
    1. Hassan-Smith G,
    2. Durant L,
    3. Tsentemeidou A, et al
    . High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis. J Neuroimmunol 2014;276:175–179.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ramsden DB
    . Multiple sclerosis: assay of free immunoglobulin light chains. Ann Clin Biochem 2017;54:5–13.
    OpenUrl
  17. 17.↵
    1. Senel M,
    2. Mojib-Yezdani F,
    3. Braisch U, et al
    . CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: a blood-CSF barrier related evaluation in a large cohort. Front Immunol 2019;10:641.
    OpenUrl
  18. 18.↵
    1. Basile U,
    2. Marino M,
    3. Napodano C, et al
    . Serological immunoglobulin-free light chain profile in myasthenia gravis patients. J Immunol Res 2018;2018:9646209.
    OpenUrl
  19. 19.↵
    1. Kerty E,
    2. Elsais A,
    3. Argov Z,
    4. Evoli A,
    5. Gilhus NE
    . EFNS/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol 2014;21:687–693.
    OpenUrlPubMed
  20. 20.↵
    1. Braber S,
    2. Thio M,
    3. Blokhuis BR, et al
    . An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:817–824.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Redegeld FA,
    2. van der Heijden MW,
    3. Kool M, et al
    . Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002;8:694–701.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Devic P,
    2. Petiot P,
    3. Simonet T, et al
    . Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol 2014;21:130–134.
    OpenUrl
  23. 23.↵
    1. Kusner LL,
    2. Puwanant A,
    3. Kaminski HJ
    . Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist 2006;12:231–239.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. van der Heijden M,
    2. Kraneveld A,
    3. Redegeld F
    . Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006;533:319–326.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Boivin D,
    2. Provencal M,
    3. Gendron S, et al
    . Purification and characterization of a stimulator of plasmin generation from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. Arch Biochem Biophys 2004;431:197–206.
    OpenUrlPubMed
  26. 26.↵
    1. Wardemann H,
    2. Hammersen J,
    3. Nussenzweig MC
    . Human autoantibody silencing by immunoglobulin light chains. J Exp Med 2004;200:191–199.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement